Daratumumab Plus Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) in Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): Final Analysis of Griffin Among Clinically Relevant Subgroups
Year: 2022
Type: article
Source: Blood
Authors: Ajai Chari, Jonathan L. Kaufman, Jacob P Laubach, Douglas W Sborov, Brandi Reeves, Cesar Rodriguez, Rebecca Silbermann, Luciano J. Costa, Larry D. Anderson, Nitya Nathwani, Nina Shah, Naresh Bumma, Sarah A. Holstein, Caitlin Costello, Andrzej Jakubowiak, Tanya M. Wildes, Robert Z. Orlowski, Kenneth H. Shain, Andrew J. Cowan, Huiling Pei, Annelore Cortoos, Sharmila Patel, Thomas S. Lin, Paul G. Richardson, Saad Usmani, Peter M. Voorhees
Institutions: Icahn School of Medicine at Mount Sinai, Emory University Hospital, Winship Cancer Institute, Harvard University, Dana-Farber Cancer Institute, University of Utah, Huntsman Cancer Institute, University of North Carolina at Chapel Hill, Tisch Cancer Institute, Oregon Health & Science University, University of Alabama at Birmingham, Harold C. Simmons Comprehensive Cancer Center, The University of Texas Southwestern Medical Center, City Of Hope National Medical Center, City of Hope, University of California, San Francisco, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, University of Nebraska Medical Center, University of California San Diego, Moores Cancer Center, University of Chicago Medical Center, The University of Texas MD Anderson Cancer Center, Moffitt Cancer Center, University of Washington, Janssen Scientific Affairs (United States), Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Memorial Sloan Kettering Cancer Center, Atrium Health Wake Forest Baptist, Levine Cancer Institute
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4310103702